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Introduction
 Crohn’s disease (CD) is defined by chronic inflammation of an isolated 
portion of the gastrointestinal track (Longo & Fauci, 2010). Frequently, the 
site of inflammation is the proximal portion of the colon, or less commonly, 
the terminal ileum (Schilling-McCann, 2008). Other names for the disease 
frequently reported in medical literature and research include regional enteritis 
and granulomatous colitis. The specific etiology of CD is idiopathic but there are 
several widely accepted theories.  
 Two of these theories are predominantly acknowledged throughout the 
medical community. According to the National Digestive Diseases Information 
Clearing House (NDDICH), a chronic autoimmune reaction to bacteria and 
specific nutrient ingestion is the most popular medical theory used to explain 
the condition (NDDICH, 2010).  Tersigni and Prantera (2010) address another 
popular explanation, suggesting the etiology of inflammatory bowel diseases is a 
genetic predisposition to dysregulation of the gastrointestinal system.  
 Various organizations and researchers have attempted to estimate the 
incidence and overall prevalence of CD resulting in a range of epidemiological 
estimates. In recent years, both the incidence and prevalence of CD have 
increased (Hyman, 2009; Loftus, Schoenfeld, & Sandborn, 2002; Neal, 2009). 
One investigation reported the incidence as rapidly increasing between the late 
1950s and early 1970s and thereafter stabilizing at roughly seven cases/100,000 
person-years (Loftus, Schoenfeld, & Sandborn, 2002). However, a recent report 
published by Digestive Disease Weekly cites a dramatic increase of 20.7% in the 
incidence during the last decade in European countries (Neal, 2009). Although 
there have not been extensive epidemiological studies in North America, many 
experts have cited it as a growing problem, linking it to many other disease of 
increasing incidence (Hyman, 2009). 
 According to the Crohn’s and Colitis Foundation of America (CCFA), 
the combined prevalence of CD and ulcerative colitis (a closely related 
disease) is currently 1.4 million in the U.S. (CCFA, 2009). The pharmaceutical 
company Nexcare Inc. (2003) estimates the prevalence of CD at 183.82/100,000 
individuals, or 1 in every 544 citizens that live in the U.S. A national survey 
throughout random communities for Irritable Bowel Syndrome (IBS; almost 
an even split between ulcerative colitis and Crohn’s) reported a standardized 
prevalence rate of 8.1% for the population (Wilson, Roberts, Roalfe, Bridge, & 
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Singh, 2004). Overall, the estimates of CD may reflect the various sampling and 
reporting techniques used in the preceding epidemiological estimations.
Risk Factors
 There is an abundance of literature addressing the possible risk factors 
that are strongly associated with CD (Braat, Peppelenbosch, & Hommes, 2006; 
Chitkara, van Tilburg, Blois-Martin, andWhitehead, 2008). While there is a 
mass of these potential variables, several have been sighted within the medical 
literature and appear to be the most commonly identified, including smoking, 
use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), and medication used 
for cystic acne (Isotretinoin).
 There is a general consensus among gastroenterologists that smoking 
is the most important modifiable risk factor for those at risk for developing CD 
(Katschinski, Logan, Edmond, & Langman, 1988). It has been shown that this 
behavior is not only detrimental to intestinal health through the inhalation of 
over 4,000 chemicals, but also increases the risk of colorectal surgery (Laghi 
et al., 2005). Several epidemiological studies have demonstrated that smoking 
cessation increases the likelihood of remission (Cosnes, Beaugerie, Carbonnel, 
& Gendre, 2001; Cosnes et al., 1999; Johnson, Cosnes, & Mansfield, 2005) with 
an even sharper increase in improvement after surgery (Reese et al., 2008). A 
study conducted by Somerville and colleagues (1984) indicated that although 
patients that smoked suffered from more severe symptoms, improvement and 
even remission was possible with smoking cessation. 
 According to Evans and colleagues (1997), there is also a strong 
association between hospital admittance of patients with CD and the use of 
NSAIDS. Additional studies have indicated NSAIDS are not the only drugs 
that are documented to increase one’s risk of developing CD. Isotretinoin 
(Accutane©), a now frequently prescribed drug used to treat acne in teenagers 
and young adults has been associated with the diagnosis of CD and Irritable 
Bowel Syndrome (Crockett, Portal, Martin, Sandler, & Kappelman, 2010; Shale, 
Kaplan, Panaccione, & Ghosh, 2009). Many teenagers that were diagnosed with 
CD were shown to have taken Isotretinoin in recent years (Margolis, Fanelli, 
Hoffstad, & Lewis, 2010). Although a direct biochemical or physiological link 
has not yet been established, the relationship between CD and these medications 
is currently being investigated (Reddy, Siegel, Sands, & Kane, 2006).
 While tobacco and certain pharmaceutical drugs have been targeted as 
strong risk factors for the disease, additional genetic, cultural, and behavioral 
factors may also play a role. Age, ethnicity, and family history have all been 
identified as contributors to a individual’s risk (Gearry, Richardson, Frampton, 
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Dodgshun, & Barclay, 2010). Findings from a study conducted by Polito and 
colleagues (1996) revealed that over 80% of those diagnosed with CD were 20 
years old or younger; and 1 out of 5 of those diagnosed had a relative that is 
affected by the condition. While a causal relationship between CD and age has 
not been identified, further epidemiological studies are needed to assess their 
potential association.
Symptoms and Diagnostic Methods
 Although CD can present in a variety of manners, the majority of 
cases exhibit symptoms of diarrhea, abdominal pain and cramping, blood in 
the fecal matter, ulcers, reduced appetite, and weight loss (Mayo Clinic, 2011). 
Less common symptoms observed include fever, fatigue, arthritis, inflammation 
of the eye, skin disorders, inflammation of the liver or bile ducts, and delayed 
growth or abnormal sexual development (Mayo Clinic, 2011). Individuals 
should seek medical attention and visit their primary care physician when they 
experience prolonged abdominal pain, observe blood in the stool following 
bowel movements, diarrhea lasting more than two days and is unresponsive to 
over-the-counter medications, or unexplained fever lasting more than 24 hours 
(Mayo Clinic, 2011).
 Most patients who have CD are unaware of it until a diagnosis has 
been made. Frequently, they will make an appointment with their primary care 
providers to discuss commonly reported digestive issues. If the provider renders 
the case as serious, the patient will be referred to a gastroenterologist. Only then, 
will endoscopy and colonoscopy be preformed in order to collect biopsy samples 
of the gastrointestinal tract. In most cases, they are taken from the colon, but 
they may be collected elsewhere, depending on where the physician believes the 
atypical cells are located in the body. The analysis of these samples is by far the 
most definitive way to diagnose the condition.
According to Chandrasoma (1999):
 Histologic examination of endoscopic biopsy samples is the best   
 method for establishing the diagnosis of IBD in a patient    
 with symptoms of colitis.  Features in the biopsy specimen permit   
 accurate differentiation of acute self-limited colitis and IBD    
 in the majority of cases (p.309). 
Chandrasoma (1999) reported that once biopsy samples have been collected, 
every effort is made by the pathologist to categorize the results as either CD or 
ulcerative colitis.
Susceptible Causes
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 The pathological components of CD have been intensely researched 
and a multitude of findings have been published on the subject. In spite of this, 
no definitive etiological process has been identified. There is some evidence that 
Escherichia coli may play a key role (Peeters, Joossens, & Vermeire, 2001), 
based upon a deficiency of defensins caused by a theoretical dysfunction of the 
NOD2/CARD15 gene (Fellermann, Wehkamp, Herrlinger, & Stange, 2003). 
This is supported by the presence of E. coli found within the ileal mucosa of 
CD patients (Darfeuille-Michaud et al., 2004). Furthermore, research conducted 
by Sasaki and colleagues (2007) documented growing strains of invasive E. 
coli cultures obtained from CD patients. During their investigation, all bacterial 
samples taken from CD patients were identified as E.coli regardless of the 
disease activity in a variety of tissues.
 A form of fungus that is conjectured as a cause of CD is Candida 
albicans (Nahas, 2011). A study published in the American Journal of 
Gastroenterology by Standaert-Vitse and colleagues (2009) reported a 
correlation between high levels of C. albicans and CD in 129 patients with a 
median age of 45 years. In addition, previous research has found that over half 
of patients who suffer from CD also exhibit higher levels of anti-S. cerevisiae 
antibodies (ASCAs; Peeters, Joossens, & Vermeire, 2001; Quinton, Sendid, & 
Reumaux, 1998). Standaert-Vitse and colleagues (2009) suggested that these 
abnormally high levels of ASCAs may be caused by C. albicans.
Treatment
 While physicians from various medical philosophies agree upon the 
diagnosis criteria for CD, there is no consensus among practitioners regarding 
proper course of treatment; and divisions exist within both conventional and 
alternative approaches. If the pathogenesis is severe, many allopathic physicians 
recommend antibiotics for treatment of the abscesses and inflammation 
(Bressler, & Sands, 2006; Greenbloom, Steinhart, Greenberg, 1998). Others 
question this theory as antibiotics are known to irritate the gastrointestinal tract 
as well as diminish the number of colonies of bacteria that have been shown to 
be the basis of the human immune system (Levy, 2000).  However, balance of 
gastrointestinal flora may be reestablished through supplementation of probiotics 
(Johnston, Supina, & Vohra, 2006). When the disease process appears to be 
stable, allopathic medicine suggests the prescription of either corticosteroids 
such as Budesonide (Entocort EC) or a form of mild chemotherapy such as 
Infliximab (Remicaid©; Benchimol, Seow, Otley, & Steinhart, 2009; Sands et 
al., 2004). 
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Conventional Treatment 
 The pathophysiological details of CD are not clear nor is there a 
definitive course of treatment leading to certain life-long remission. Due to 
this difficulty, the conventional treatment for CD is highly debated. Therefore 
allopathic practitioners utilize a variety of pharmacological therapeutic 
modalities, all of which seek remission in the patient for as long as possible 
(Lichtenstein, Hanauer, & Sandborn, 2009).
Sellin and Pasrichia (2006) state:
 Medical therapy for Irritable Bowel Disease is problematic. Because no  
 unique abnormality has been identified, current therapy seeks to   
 dampen the generalized inflammatory response; however no    
 agent can readily accomplish this, and the response of an individual   
 patient to a given medicine may be limited and unpredictable (p. 1009). 
 Following conventional allopathic medical philosophy, treatment 
is selected based upon the severity of the disease process at the time it is 
to be rendered (Akobeng, 2008; Clarke & Regueiro, 2009; Colombel, et 
al., 2010; Schwartz, Pemberton, & Sandborn, 2001). Patients experiencing 
mild symptoms are advised to take over-the-counter medications to manage 
symptoms, such as Loperamide for diarrhea, milk of magnesia for constipation, 
and iron supplements to treat deficiency caused by excessive bowel movements 
(Hanauer, 2008). For patients experiencing mild to moderate symptoms, 
there are several classes of pharmaceuticals that can be utilized to reduce 
the intensity of symptoms and/or promote induction of remission (Akobeng, 
2008). Though there is much debate on the proper course of treatment, 
physicians typically select a medication based on the intensity of the symptoms. 
Commonly prescribed drug classifications include: aminosalicylates, antibiotics, 
corticosteroids, immunosuppressants, biologics, rifaximin, tacrolimus (Sellin & 
Pasricha, 2006).
 For those that experience mild to moderate symptoms, one of several 
medications may be prescribed. Mesalamine (5-aminosalicylic acid, 5-ASA) 
and sulfasalazine is generally used as the “first line of defense” for CD (Sellin 
& Pasricha, 2006). However, Sulfasalazine has not been shown to be efficacious 
in the maintenance of remission and more recently other 5-ASA preparations 
have been prescribed (Sellin & Pasricha, 2006).  Two of these new preparations, 
Pentasa (mesalamine) and Asacol (mesalamine) have become popular in the 
gastrointestinal community due to their rate of admittance into remission (Lim 
& Hanauer, 2010). There is no clear benefit of continuing this type of therapy 
once patients enter remission. This causes their use as a maintenance drug to be 
controversial (Sellin & Pasricha, 2006).
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Glucocorticoids and steroids may also be used as treatment for mild to moderate 
symptoms, depending on whether the case of CD is steroid-responsive, 
steroid-dependent, or steroid-unresponsive (Lemann et al., 2006). In ideal 
cases, steroid-responsive patients will show improvement within 1-2 weeks 
of treatment and remain in remission. Future steroid use is tapered off and 
eventually discontinued (Sellin & Pasricha, 2006). Patients classified as “steroid-
dependent” respond to initial treatment administration yet their symptoms begin 
to reoccur after the treatment is tapered off or stopped. Approximately 40% 
of patients are steroid-responsive, 30% to 40% have only a partial response or 
become steroid-dependent, and 15% to 20% do not respond to steroid therapy at 
all (Sellin & Pasricha, 2006).
 Thiopurine derivatives are prescribed for patients who are experiencing 
moderate to severe symptoms of CD and are either steroid dependent or steroid 
resistant (Sellin & Pasricha, 2006). Mercaptopurine (6-MP), known on the 
market as Purinethol®, and Azathioprine, known commonly as Immuran are 
two of the most commonly used thiopurines for CD (Sellin & Pasricha, 2006). 
Both have been shown to be successful in inducing remission but are sometimes 
viewed as non-viable options due to the uncomfortable side effects experienced 
in some patients, such as nausea, vomiting, diarrhea, and loss of appetite. In 
addition, thiopurines may take several weeks or months to induce therapeutic 
effects in patients making them the less desirable choice for acute symptoms or 
flare-ups (Sellin & Pasricha, 2006).
 Methotrexate, originally developed as an anti-cancer drug, was later 
recognized as an effective treatment for psoriasis and rheumatoid arthritis (Sellin 
& Pasricha, 2006). Since the 1990s, Methotrexate has also been shown to be 
useful in the treatment of CD, with current research still supporting this data 
(Chande, Abdelgadir, & Gregor, 2011; Feagan et al., 1995). It is also typically 
reserved for patients who are steroid-resistant or steroid-dependent (Sellin & 
Pasricha, 2006). Known for its ability to induce and maintain remission, it 
can be a desirable choice due to a patients’ quick response to its therapeutic 
properties (Alfadhli, McDonald, & Feagan, 2005).
 A relatively new form of biologics, anti-tumor necrosis factor alpha 
(TNF- α) therapy, has become an extremely popular treatment option for CD in 
the last decade. TNF- α binds with a chimeric immunoglobin causing it to 
become neutralized (Panés et al., 2007). There are many different cytokines 
generated in the intestine of a patient suffering from CD but there is rationale 
suggesting TNF- α is one of the principal cytokines mediating the TH1 immune 
response, a primary immunological characteristic of the disease (Sellin & 
Pasricha, 2006).
 Infliximab (Remicaid©) is a relatively new pharmaceutical, and has 
been established as beneficial for CD patients. Two-thirds of patients with 
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moderate to severe cases indicate a decrease in the frequency of acute flares 
when treated with Infliximab (Sellin & Pasricha, 2006). Though its use as a 
long-term treatment has yet to be thoroughly ascertained, current research 
supports the medication’s efficacy in preventing the recurrence of fistulas 
and maintaining remission (Present et al., 1999; Schröder, Blumenstein, 
Schulte-Bockholt, & Stein, 2004). While it may seem like a panacea, there 
is also data that causes practitioners to heed caution due to adverse side 
effects, both acute and sub-acute. Some of the adverse effects include fever, 
chills, urticarial, anaphylaxis, and serum sickness (Sellin & Pasricha, 2006). 
Therapy with Infliximab has also been shown to increase the incidence of 
respiratory infections, reactivity of tuberculosis, and complications in patients 
with congestive heart failure (Sellin & Pasricha, 2006). In addition, it shares 
an association of increased incidence of non-Hodgkin’s lymphoma, as is 
the case with most immunosuppressants (Bebb & Logan, 2001; Lakatos & 
Miheller, 2010). More research is needed to fully understand the beneficial 
effects of medications used to reduce TNA-α. For example, Etaneracept have 
demonstrated limited efficacy. Furthermore, additional research is needed to 
explore potential methods to limit the side effects of medications that have been 
identified as beneficial for CD patients.
 Antibiotics may be used to treat CD for a number of reasons, including 
prophylaxis for recurrence in postoperative CD, treatment for a specific 
complication of CD, or adjunctive treatment along with other medications 
for active CD (Feller et al., 2010). The most frequently used antibiotics are 
Metronidazole, Ciprofloxacin, and Clarithromycin (Sellin & Pasricha, 2006). 
Each of these pharmaceutical substances are more beneficial for different types 
of cases in patients with the disease (Sellin & Pasricha, 2006).  However, recent 
research has shown that prolonged use of antibiotics can disturb the balance 
of intra-intestinal bacteria flora, resulting in the worsening of the pathogenesis 
(Guarner & Malagelada, 2003). Probiotics supplements have demonstrated an 
efficacy to restore this balance by populating the intestines with the bacteria 
lost through prophylaxis with antibiotics (Cary & Boullata, 2010; Damaskos, 
& Kolios, 2008; D’Souza, Rajkumar, Cooke, & Bulpitt, 2002; Gionchetti et al., 
2006; Guarner & Malagelada, 2003; Kanauchi, Mitsuyama, Araki, & Andoh, 
2003; Kwon & Farrell, 2003; Quigley, & Quera, 2006; Sans, 2009; Sartor, 2004; 
Kruis, 2004).
 If the patient must be hospitalized in order for the disease to be 
suppressed, enteral nutrition is commonly advised (Tsujikawa, Andoh, 
& Fujiyama, 2003). A recent study conducted by the Department of 
Gastroenterology at Nagoya University Graduate School of Medicine in Nagoya, 
Japan, reported a significant decrease in hospital admissions from complications 
in CD patients due to improvement through enteral nutrition targeting a specific 
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caloric intake (Watanabe et al, 2010). Caution must be taken though, as it has 
long since been discovered that this can lead to a severe selenium deficiency 
if the treatment is maintained over a long period of time (van Rij, Thompson, 
McKenzie, & Robinson, 1979; Sikora, Spady, Prosser, & El-Matary, 2011). 
However, this deficiency can be corrected by selenium supplementation (Baker 
et al., 1983).
 Surgery is considered if the bowel becomes necrotic or if there is 
evidence of a perforation. Surgeons and gastrointestinal specialists concur that 
this must be viewed as a last resort, for the bowel does not regenerate and is 
very sensitive to invasive procedures. Because of this, all treatment options 
are usually exhausted before surgery is considered, excluding cases of extreme 
circumstances such as trauma or complete perforation (Peyrin-Biroulet et al., 
2011; Slattery, Keegan, Hyland, O’donoghue, & Mulcahy, 2011). 
Alternative Treatment
 As research concerning the contributing factors of CD continues to 
develop, the involvement of diet and nutrition have been established as relevant 
components (Lucendo & De Rezende, 2009). A study in The European Journal 
of Clinical Nutrition found carbohydrate consumption to be much higher in 
CD patients than in comparative control groups (Geerling, Badart-Smook, 
Stockbrügger, & Brummer, 2000). There has been speculation that a diet 
primarily consisting of processed foods could be a risk factor for CD. There 
have been studies from as early as 31 years ago reporting increased intake of 
refined sugars in patients with CD (Mayberry, Rhodes, & Newcombe, 1980; 
Thornton, Emmett, & Heaton, 1979). Another study following patients placed 
on a dietary regimen of unrefined carbohydrates reported an 80% decrease in 
hospitalization when compared to a control group of patients without dietary 
guidelines (Heaton, Thornton, Emmett, 1979). Additional research not only 
supports the excess of refined sugars in the diet as a risk factor for CD, but a 
lack of raw fruits in vegetables in the diet as well (Thornton et  al., 1979).
 Naturopathic physicians also advise nutrition for the treatment of CD, 
only they suggest nutrient rich foods such as fruits and dark green vegetables 
as well as orthomolecular doses of certain minerals including magnesium, 
selenium, and zinc (Rannem, Ladegoded, Hylander, Hegnhoj, & Jarnum, 1992). 
Nutritional therapy can be very useful in the treatment of CD, especially in the 
case of children. It has been cited as a successful treatment in the control of 
inflammation and mucosal healing, exhibiting positive benefits to growth and 
overall nutritional status with minimal adverse effects (Hartman, Eliakim, & 
Shamir, 2009). Recently published research reveals the advantages of elemental 
diet as a maintenance treatment for CD (Takagi et al., 2006). This has been 
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shown to be beneficial in lowering the rate of relapse in patients, as well as 
provide an alternative for those that cannot tolerate pharmaceuticals such as 
thiopurines (Takagi et al., 2006).  Research by Rajendran and Kumar (2010) 
demonstrates successful remission in patients with CD by eliminating foods 
causing unwanted reactions from the diet. They hypothesize that remission 
may be achievable through this method entirely, without reliance upon 
pharmacological aids.
Conclusion
 There is still no known cure for CD, although there are several 
treatment theories available for the condition. Comparatively, we know very 
little about CD versus other chronic diseases. Because of this, future research is 
needed to understand the etiological factors, treatment options, and preventive 
approaches to the disease. This includes biomedical research and investigations 
concerning not only the pathophysiology on a molecular and cellular level, 
but also a holistic approach to treatment. Through research, we have seen that 
allopathic treatment can help patients gain remission quickly, but soon after 
patients fail to maintain this status. Moving forward, holistic practitioners 
continue to question the possible treatment options through rigid medical 
nutrition therapy, as well as herbalism and naturopathic medicine. As the 
prevalence of CD increases, it has become more evident that future research is 
needed to create efficacious treatment options, eventually resulting in a cure.
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